Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy. It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication. Delamanid has been granted orphan drug status in both the EU and Japan. This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-014-0241-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond the Nest: The Role of Financial Independence in Young Adult Health.
Int J Behav Med
January 2025
Department of Psychology, Georgia State University, 140 Decatur Street, Suite 1150 Urban Life Building, Atlanta, GA, 30303, USA.
Background: This study aimed to examine the impact of neighborhood conditions and household material hardship experiences on young adult health outcomes, while also considering financial autonomy as a critical determinant of health.
Method: We employed a cross-sectional observational design with a diverse sample of young adults from a large urban university. Structural equation modeling was used to analyze the relationships between neighborhood conditions and material hardship with health outcomes by financial autonomy.
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.
Curr Treat Options Oncol
January 2025
Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.
Integrating clinical datasets in breast cancer research emerges as a necessary tool for advancing our knowledge of the disease and enhancing patient outcomes. Synthesizing diverse datasets offers advantages, from facilitating evidence-based insights to enabling predictive analytics and precision medicine strategies. Crucially, effective integration of clinical datasets necessitates collaborative efforts, policy interventions, and technological advancements to elevate global standards of breast cancer care.
View Article and Find Full Text PDFGlobal, regional, and national trends in type 2 diabetes mellitus burden among adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021.
World J Pediatr
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Background: Type 2 diabetes mellitus (T2DM) poses an escalating public health challenge among adolescents and young adults worldwide. Despite the rising incidence, comprehensive data on the burden and trends of T2DM in this demographic remain scarce. This study aims to evaluate the burden of T2DM among individuals aged 10-24 years globally, regionally, and nationally from 1990 to 2021.
View Article and Find Full Text PDFGroup 3 Innate Lymphoid Cells: A Potential Therapeutic Target for Steroid Resistant Asthma.
Clin Rev Allergy Immunol
December 2024
Division of Allergy and Clinical Immunology, The Johns Hopkins Asthma & Allergy Center, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Room 3B.71, Baltimore, MD, 21224, USA.
Asthma is a chronic airway inflammatory disease that affects millions globally. Although glucocorticoids are a mainstay of asthma treatment, a subset of patients show resistance to these therapies, resulting in poor disease control and increased morbidity. The complex mechanisms underlying steroid-resistant asthma (SRA) involve Th1 and Th17 lymphocyte activity, neutrophil recruitment, and NLRP3 inflammasome activation.
View Article and Find Full Text PDFAQbD integrated High-Performance Thin Layer Chromatographic Method for Quantitative Estimation of Tavaborole in the presence of its degradants and the matrix of nanostructured lipid carriers.
Drug Dev Ind Pharm
January 2025
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), Changa - 388421, Anand, Gujarat, India.
Background: Tavaborole (TAV), a benzoxaborole derivative, is an FDA-approved antifungal agent for treating onychomycosis, a common and persistent fungal infection of the toenails.
Objective: This study aimed to develop a robust stability-indicating HPTLC method to determine TAV in nanostructured lipid carriers (NLC) using a comprehensive approach that includes risk assessment, and Analytical Quality by Design.
Methods: The critical method parameters influencing the HPTLC results were screened using a Placket-Burman screening design followed by its optimization using a central composite optimization design.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!